# Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction

Study · id `cardio:ct-nct04798430` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04798430](<https://clinicaltrials.gov/study/NCT04798430>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT04798430

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2000 participants.

## Technical summary

Registry record NCT04798430. Allocation not applicable; no masking; primary purpose treatment. Start 2020-12-03 (actual); primary completion 2025-07-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2000 participants (planned count; ClinicalTrials.gov record NCT04798430, source copy `cardio:ctgov-nct04798430-2024-10-22`, retrieved 2026-11-18)
- Started: 2020-12-03 (actual) (ClinicalTrials.gov record NCT04798430, source copy `cardio:ctgov-nct04798430-2024-10-22`, retrieved 2026-11-18)
- Primary completion: 2025-07-30 (anticipated) (ClinicalTrials.gov record NCT04798430, source copy `cardio:ctgov-nct04798430-2024-10-22`, retrieved 2026-11-18)
- Completion: 2025-12-31 (anticipated) (ClinicalTrials.gov record NCT04798430, source copy `cardio:ctgov-nct04798430-2024-10-22`, retrieved 2026-11-18)
- Countries: United States; India; Israel; Norway; South Africa; Türkiye (ClinicalTrials.gov record NCT04798430, source copy `cardio:ctgov-nct04798430-2024-10-22`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04798430-2024-10-22`, retrieved 2026-11-18)

## The registry's words

- Brief title: Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction
- Acronym: LIBerate-OLE
- Condition: Cardiovascular Disease With Mention of Arteriosclerosis
- Condition: Elevated Cholesterol
- Condition: Familial Hypercholesterolemia
- Intervention (Drug): lerodalcibep
- Lead sponsor: LIB Therapeutics LLC
- Lead sponsor class: INDUSTRY
- Collaborator: Medpace, Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Familial hypercholesterolemia (`cardio:familial-hypercholesterolemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: LIB Therapeutics LLC (`cardio:org-lib-therapeutics-llc`)
- Registry lists this organization as a collaborator: Medpace, Inc. (`cardio:org-medpace-inc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Response to PCSK9 Inhibition Based on LDL Receptor Function in Familial Hypercholesterolemia: A Nonrandomized Clinical Trial (`cardio:pubmed-42054033`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 3104b60797b0a0ffad04bf1626ee1f4e422e45ab159e63c26c5c52654dc538dc
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
